Variables | Participants | Nonparticipants | p |
---|---|---|---|
Female, % | 92 (93.9) | 647 (89.0) | 0.138 |
White, % | 55 (56.1) | 441 (60.7) | |
Age, yrs, mean ± SD | 45.38 ± 11.50 | 46.72 ± 15.12 | 0.536 |
Age at SLE diagnosis, yrs, mean ± SD | 31.64 ± 10.21 | 29.24 ± 12.56 | 0.396 |
SLE disease duration, yrs, mean ± SD | 18.52 ± 12.05 | 17.48 ± 11.31 | 0.397 |
Education, yrs, mean ± SD | 15.24 ± 2.91 | 14.26 ± 2.57 | < 0.001 |
SLEDAI-2K, mean ± SD | 3.37 ± 4.30 | 3.62 ± 4.05 | 0.564 |
SDI score, mean ± SD | 1.84 ± 2.15 | 1.48 ± 1.84 | 0.083 |
CVE (TIA, angina, MI, CHF), % ever | 10.2 | 6.5 | 0.155 |
Hypertension, % ever | 62.2 | 68.9 | 0.315 |
Diabetes, % ever | 8.2 | 7.8 | 0.36 |
aPL, % ever | 15.3 | 33.4 | 0.349 |
aPL, % past 5 yrs | 10.2 | 11.0 | 0.278 |
aPL syndrome ever | 15.3 | 15.1 | 0.964 |
Dyslipidemia, % ever | 82.7 | 68.9 | 0.016 |
Smoker, % past 5 yrs | 17.3 | 11.6 | 0.092 |
Glucocorticoid treatment, % current use | 90.8 | 83.4 | 0.057 |
Glucocorticoid dose, mg/day, mean ± SD | 5.7 ± 7.4 | 5.96 ± 10.59 | 0.807 |
The percentage of patients who were approached and agreed to participate in this study is not available. SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; CVE: cardiovascular event; TIA: transient ischemic attack; MI: myocardial infarction; CHF: congestive heart failure; aPL: antiphospholipid antibodies.